MOTS-c vs Humanin: Two Mitochondrial Peptides, Different Targets
Here is how these two compounds compare — based on published research, not marketing claims.
MOTS-c
194
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Humanin
255
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
MOTS-c and humanin share an unusual origin — both are encoded by mitochondrial DNA, not nuclear DNA. Your mitochondria produce them as signaling molecules. But they signal different things. MOTS-c tells your cells to improve energy metabolism. Humanin tells your cells to survive under stress. One is about performance. The other is about protection.
Key Differences
| Attribute | MOTS-c | Humanin |
|---|---|---|
| Evidence Level | Human Trials | Animal Studies |
| Category | Mitochondrial-Derived Peptide | Mitochondrial-Derived Peptide |
| Human Data | Five human studies. Metabolic effects observed. PSI rates L3. | Primarily observational. Human studies correlate humanin levels with health outcomes. Interventional studies are limited. PSI rates L2. |
| Safety Profile | Limited but favorable. Endogenous peptide. No serious adverse events reported. | Limited data. Endogenous peptide. Theoretical safety is favorable. |
| Key Limitations | Human data is early-stage. Long-term effects unknown. | Less interventional human data than MOTS-c. Most research is mechanistic or correlational. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
MOTS-c
Activates AMPK, the master metabolic switch. Improves insulin sensitivity, enhances fatty acid oxidation, and mimics some effects of exercise. Your mitochondria produce less of it as you age.
Humanin
Binds to cell-surface receptors (FPRL1 and others) to activate anti-apoptotic signaling. Protects cells from programmed death under stress conditions. Think of it as an emergency survival signal from the mitochondria.
MOTS-c improves how cells use energy. Humanin prevents cells from dying. MOTS-c activates AMPK to boost metabolism. Humanin activates anti-death pathways to keep stressed cells alive. Both come from mitochondria. Both decline with age. But they protect against aging in different ways.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 449 indexed studies. Here are the key findings.
MOTS-c is L3 with five human studies showing metabolic effects. Humanin is L2 with primarily correlational human data. MOTS-c has more interventional evidence. Humanin has a broader mechanistic profile but less clinical validation.
For metabolic optimization and exercise mimetic effects, MOTS-c has more relevant data.
For neuroprotection and cell survival under stress, humanin has the more specific mechanism.
For aging research broadly, both represent the frontier of mitochondrial medicine.
For available human evidence, MOTS-c is slightly ahead.
Key Limitations
- •No head-to-head comparison.
- •Both are early in clinical development.
- •Humanin's correlational data does not prove causation.
- •The mitochondrial-derived peptide field is young — much is still being discovered.
PSI Verdict
SUPPORTED BY EVIDENCE
MOTS-c activates AMPK and improves metabolic function in five human studies. Humanin levels correlate with better health outcomes in observational human studies and protect cells from apoptosis in preclinical models.
NOT YET ESTABLISHED
Whether supplementing either peptide meaningfully slows aging in humans is unproven. Humanin's observational correlations do not establish causation. MOTS-c's metabolic effects have not been linked to hard clinical outcomes.
CONFIDENCE LEVEL
Moderate for MOTS-c based on its human metabolic data. Low-moderate for humanin based on primarily correlational evidence. Both are at the frontier. MOTS-c is slightly ahead in clinical validation.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MOTS-c
"MOTS-c is the longevity peptide everyone should be taking"Plausible but unproven
"It improves exercise performance and endurance"Supported by published data
"People are using it as a metabolic reset"Anecdotal only
Humanin
"Humanin is the anti-Alzheimer's peptide"Plausible but no human therapeutic data
"High humanin levels are found in centenarians"Supported by evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
MOTS-c
Limited but favorable. Endogenous peptide. No serious adverse events reported.
Humanin
Limited data. Endogenous peptide. Theoretical safety is favorable.
Both are endogenous. Both have limited clinical safety data. Theoretical safety is favorable for both. No serious concerns have emerged.
WHAT THE RESEARCH SUGGESTS
Both are fascinating signals from an unexpected source — mitochondrial DNA. MOTS-c is further along clinically for metabolic effects. Humanin has broader protective potential but less interventional evidence.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.